reason report
doublet gain access scotland long-term agreement
bottom line today vertex announc reach
year agreement nh scotland immedi access
orkambi symkevi combin ivacaftor cystic fibrosi
cf negoti price disclos expect
scottish govern pay close germani
orkambi symkevi though interim agreement may gener
signific revenu base elig patient
encourag vertex make progress one import
market cf medicin outsid us importantli
agreement place scotland along earlier agreement
republ ireland increas pressur nh agre
price access england wale northern ireland
cf patient still untreat elig orkambi/
symkevi accord estim unclear vertex press
releas whether agreement also cover futur access tripl
combin assum includ similar slightli lower
price due larger patient elig
base latest result total ou sale cf drug
reach growth yoy high growth
primarili driven strong sale germani due launch symkevi
current forecast total ou sale reach
grow slightli tripl combin
launch expect earli ou rel flat forecast
base assumpt continu stand-off
govern payer uk franc though agreement
materi enough trigger model updat forecast could increas
materi vertex reach long-term agreement uk franc
reason price near term
high prioriti secur agreement uk franc portfolio
agreement seem like despit rel broad reimburs
coverag develop countri australia germani
anoth countri vertex cf drug limit access two
largest market indic uk franc
quarter global cf market term patient number
previous reduc ou revenu forecast account
challeng eu reimburs environ note
downgrad vertex stock lower outlook base eu impass
stock fulli valu despit lower forecast ou revenu
forecast still account signific part total cf revenu forecast
given context
prior negoti think portfolio agreement uk franc
like realist price probabl close
patient/year uk propos cf patent
chang forecast scotland agreement
near term ou revenu forecast larg limit uk franc
pleas refer page import disclosur price chart analyst certif
reimburs impass ou growth come
germani ou countri
geoffrey porg mbb certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori vertex pharmaceut incorpor
leerink place outperform rate februari
creat bluematrix
price target vertex base simpl averag three approach believ reason
basi valu stock today approach simpl price earn multipl higher growth larg cap
biopharmaceut compani price sale multipl mid larg cap high growth biopharmaceut compani
discount cash flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim discount back year
compani cost equiti give valu one year use averag high growth larg cap biotech
price-to-revenu multipl sale appli
revenu estim post-tripl discount back year compani cost equiti give
valu one year lastli dcf valuat given wacc termin cash flow growth rate
give present valu averag three method current price target
risk valuat
risk view outlook valuat vertex includ major chang price reimburs
coverag label competit posit kalydeco orkambi compani main product today
major risk disappoint delay failur compani develop regulatori file novel tripl
combin medicin cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cftr altern approach
treat cf gene therapi final compani histori spend much potenti earn
expens diversifi acquisit could undermin futur expect valu compani cf portfolio
opportun better-than expect perform includ realiz signific revenu compani
current cf dual combin market outsid us well acceler clinic develop tripl
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
